BofA analyst Tim Anderson raised the firm’s price target on Aardvark Therapeutics (AARD) to $26 from $22 and keeps a Buy rating on the shares after Soleno Therapeutics (SLNO), a competitor to Aardvark, received FDA approval for treating hyperphagia associated with Prader-Willi syndrome in patients 4 and older under the brand name Vykat XR. The firm views the competitor’s news “favorably” for Aardvark and as partially de-risking for ARD101.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Aardvark Therapeutics initiated with an Outperform at RBC Capital
- Aardvark Therapeutics initiated with a Buy at BofA
- Aardvark Therapeutics initiated with an Overweight at Morgan Stanley
- Opening Day: Kestra opens for trading, Discord discusses potential IPO
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue